Vaxxas, a biotechnology company commercializing a novel vaccination platform, announced Merck, known as MSD outside of the United States and Canada, has exercised its option to utilize Vaxxas’ proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate.